Research Article
Cost-Effectiveness Evaluation of Etoricoxib versus Celecoxib and Nonselective NSAIDs in the Treatment of Ankylosing Spondylitis in Norway
Table 2
Individual studies and results included for mixed treatment comparison of BASFI, BASDAI and discontinuation due to lack of efficacy.
| | Placebo | Celecoxib | Naproxen* | Etoricoxib | Diclofenac* | | | | 200 mg | 400 mg | 1000 mg | 90 mg | 150 mg | | Mean | (SE) | Mean | (SE) | Mean | (SE) | Mean | (SE) | Mean | (SE) | Mean | (SE) |
| | BASFI |
| | Barkhuizen et al. [26] | 2.00 | (3.00) | −9.00 | (0.50) | −11.00 | (1.00) | −16.00 | (2.00) | | | | | | Van der Heijde et al. [16] | −4.00 | (1.90) | | | | | −14.60 | (1.80) | −19.40 | (1.80) | | | | Dougados et al. [27] | 1.30 | (2.03) | −11.90 | (2.46) | | | | | | | | | | Sieper et al. [17] | | | −8.00 | (1.62) | −9.00 | (1.23) | | | | | −9.00 | (1.45) |
| | BASDAI |
| | Van der Heijde et al. [16] | −6.40 | (1.90) | | | | | −23.6 | (1.80) | −28.60 | (1.80) | | | | Sieper et al. [17] | | | −9.90 | (1.71) | −13.20 | (1.40) | | | | | −14.80 | (1.41) |
| | Discontinuation for lack of efficacy and (sample size) |
| | | | | | | | | | | | | |
| | Barkhuizen et al. [26] | 59 | 156 | 25 | 137 | 23 | 161 | 17 | 157 | | | | | | Van der Heijde et al. [16] | 44 | 93 | | | | | 20 | 97 | 8 | 100 | | | | Dougados et al. [27] | 31 | 76 | 18 | 80 | | | | | | | | |
|
|
*For mixed treatment comparison of BASDAI, the results of naproxen and diclofenac were considered as the group nsNSAID.
|
